NCT03424330

Evaluation of ReX-C System in Measurement and Improvement of Patients' Adherence.

Evaluation of ReX-C System in Measurement and Improvement of Adherence, in Patients Receiving Oral Anti-coagulation Therapy for the Treatment and Prevention of Thromboembolism.

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Dosentrx Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study aims to evaluate the safety, usability and efficacy of the ReX-C - a novel medication management system - in measurement and improvement of adherence, in patients receiving oral anti-coagulation therapy for the treatment and prevention of thromboembolism.

Detailed description

ReX-C is a mobile system intended to provide solid, oral medication on patient demand, according to a pre-programmed treatment protocol. ReX-C addresses poor adherence to medication therapy by providing real-time, reliable adherence data to caregivers and timely, personalized reminders to patients. During the study, the use of ReX-C system to receive medications will be compared to Standard of Care. Patients' adherence will be evaluated for both methods.

Conditions

• Thromboembolism

Interventions

Type	Name	Description
DEVICE	ReX-C intervention	Patients receive medication by the ReX-C device
OTHER	Standard of Care	Patients receive medication as usual

Timeline

• Start date: 2019-01-09
• Primary completion: 2023-12-25
• Completion: 2023-12-25
• First posted: 2018-02-07
• Last updated: 2023-12-12

Locations

1 site across 1 country: Israel